Gesynta Pharma presents e-poster on vipoglanstat at SEUD 2024 in Geneva

Our e-poster, presented at the SEUD conference in Geneva, sparked lively discussions and significant interest in vipoglanstat, a novel, non-hormonal compound in development for the treatment of endometriosis. We highlighted the drug's potential to address critical unmet needs, focusing on its promising pain-relieving effects demonstrated in disease models and its proven safety profile in initial human studies.

The conference of the Society of Endometriosis and Uterine Disorders (SEUD) provided an excellent forum to connect with leading researchers and clinicians in the field. We enjoyed sharing insights on vipoglanstat's mechanism of action – selective mPGES-1 inhibition – and exploring potential collaborations to advance its development.

The development of vipoglanstat aligns perfectly with SEUD’s mission to provide an international platform for scientific advancements that benefit patients with endometriosis and uterine disorders. Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.